The Worldwide Market for Cancer Diagnostics, 3rd Edition

The Worldwide Market for Cancer Diagnostics, 3rd Edition

Who are the major players in testing for the number two killer in the world? What revenues can companies competing in this market expect in the next five years? How will the impact of trends such as an increased role of pharmacodiagnostics, the use of multiplex assays and a new emphasis on service products influence cancer diagnostics?

These questions and more are answered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition. This report contains detailed market data on the following areas of cancer diagnostics:

• Histology/Cytology
  
  
• Immunoassays
  
  
• Flow Cytometry
  
  
• Rapid Tests
  
  
• Molecular Assays
  
  
• Tissue Arrays
  
  
• Circulating Tumor Cells
  
  
• Pharmacodiagnostics

Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition represents the third time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:

• Pap Smear Testing Volumes
  
  
• DNA Reagents for Cancer Testing
  
  
• CTC Testing Markets
  
  
• Major Protein and Molecular Markers Used in Tissue Staining
  
  
• Microarray Markets in Clinical Labs
  
  
• Lists of Vendors and Major Products

This report includes detailed market analysis of the following screening tests:

• DR-70
  
  
• HAAH
  
  
• ECPKA
  
  
• The Cancer Profile
  
  
• CTC
  
  
• Fecal Occult Blood
  
  
• PSA
  
  
• H. pylori
  
  
• IHC
  
  
• ISH

As well as tests for specific cancers:

• Bladder Cancer
  
  
• Breast Cancer
  
  
• Cervical Cancer
  
  
• Colon Cancer
  
  
• Lung Cancer
  
  
• Ovarian Cancer
  
  
• Prostate Cancer

This latest edition of Kalorama’s study takes a fresh look at all of these developments both qualitatively and quanititatively. The report provides revenue and growth forecasts through 2012 and, as in the previous edition, analyzes the market in two ways:

• Tests for specific cancers, and
  
  
• Cancer tests in specific IVD segments

This allows the reader to match his or her own situation to the market at large.

In addition to extensive reviews of products on the market and in development in each segment, the report also provides the most extensive review of innovative companies yet compiled in this market with profiles of over 150 companies active in the segment.

Kalorama's diagnostics industry analyst Shara Rosen provides the rigorous analysis and thoughtful research that has been made her market reports the backbone of diagnostic market decision-making for years.

The following companies were profiled in this report:

• 20/20 GeneSystems Inc.
  
  
• 454 Life Sciences Corporation
  
  
• A&G Pharmaceutical
  
  
• AdnaGen AG
  
  
• Affymetrix Inc.
  
  
• Agendia B.V.
  
  
• Agilent Technologies Inc.
  
  
• Alethia Biotherapeutics Inc.
  
  
• Almac Diagnostics (formerly ArraDx)
  
  
• Althea Technologies, Inc.
  
  
• Ambrilia Biopharma Inc.
  
  
• AMDL, Inc.
  
  
• American Diagnostica Inc.
  
  
• Aperio Technologies, Inc.
  
  
• Applied Genomics, Inc. (AGI)
  
  
• Applied Imaging Corp./Genetix
  
  
• Asuragen, Inc.
  
  
• AsymmetRx, Inc.
  
  
• AviaraDx (formerly Arcturus Biosciences)
  
  
• AVIVA Biosciences Corporation
  
  
• BioCurex, Inc.
  
  
• BioGenex Laboratories, Inc.
  
  
• BioImagene, Inc.
  
  
• Biomoda, Inc.
  
  
• BioMosaics
  
  
• BioNanomatrix
  
  
• Biophysical Corp.
  
  
• BioServe
  
  
• Biosite Incorporated
  
  
• BIOVIEW, Inc.
  
  
• Bostwick Laboratories, Inc.
  
  
• Bruker BioSciences Corporation
  
  
• CCC Diagnostics LLC
  
  
• Cancer Genetics, Inc.
  
  
• Cangen Biotechnologies, Inc.
  
  
• Celera
  
  
• Celerus Diagnostics
  
  
• Cellumen, Inc.
  
  
• CeMines, Inc.
  
  
• ChemSensing
  
  
• Clarient Inc. (formerly ChromaVision)
  
  
• CombiMatrix Molecular Diagnostics (CMDX)
  
  
• CompuCyte Corporation
  
  
• Correlogic Systems, Inc.
  
  
• CytoCore, Inc. (formerly Molecular Diagnostics, Inc.)
  
  
• Cytyc Corporation
  
  
• Dako A/S
  
  
• diaDexus Inc.
  
  
• DiaGenic ASA
  
  
• DiagnoCure
  
  
• Diamics, Inc.
  
  
• Digene Corporation (Acquired by Qiagen)
  
  
• DNA Direct, Inc.
  
  
• DxS
  
  
• eGene Inc.
  
  
• Epigenomics AG
  
  
• EXACT Sciences Corporation
  
  
• eXagen Diagnostics, Inc.
  
  
• Exiqon A/S
  
  
• Falcon Genomics, Inc.
  
  
• Fermiscan Holdings Limited (FER)
  
  
• Fluidigm Corporation
  
  
• Fujirebio Diagnostics. Inc. (FDI)
  
  
• GeneNews Limited (formerly ChondroGene Limited)
  
  
• GenoMed, Inc.
  
  
• Genomic Health
  
  
• Genoptix Inc.
  
  
• Gen-Probe Incorporated
  
  
• Genzyme Corporation
  
  
• Greiner Bio-One International AG
  
  
• Gynecor
  
  
• Health Discovery Corporation
  
  
• HistoRx, Inc,
  
  
• Ikonisys Inc.
  
  
• Illumina
  
  
• ImmunArray Ltd.
  
  
• Immunicon Corporation
  
  
• Immunotope, Inc.
  
  
• InterGenetics, Inc.
  
  
• Invirion Diagnostics, LLC
  
  
• Ipsogen
  
  
• Kronus Inc.
  
  
• Laboratory Corporation of America Holdings (LabCorp)
  
  
• Luminex Corporation
  
  
• MacroArray Technologies, LLC
  
  
• Matritech
  
  
• MDS/Molecular Devices Corporation
  
  
• Med BioGene, Inc. (MBI)
  
  
• Menssana Research, Inc.
  
  
• Micronics Inc.
  
  
• Miraculins Inc.
  
  
• Modern Technology Corp.
  
  
• MolecularMD
  
  
• MonoGen
  
  
• Monogram Biosciences Inc. (formerly Virologic, Inc.)
  
  
• mtm laboratories AG
  
  
• Myriad Genetics, Inc.
  
  
• NeoMatrix, LLC
  
  
• NorChip
  
  
• NorDiag ASA
  
  
• Nuvera Biosciences
  
  
• Olympus Life and Material Science Europa, GMBH
  
  
• Onco Detectors International LLC
  
  
• Oncolab Inc.
  
  
• OncoMethylome Sciences S.A.
  
  
• Onconome, Inc. (formerly Tessera Diagnostics)
  
  
• One Cell Systems, Inc.
  
  
• Orion Genomics
  
  
• Oxford Genome Sciences Ltd. (OGeS)
  
  
• OXIS International
  
  
• Pacific Edge Biotechnology Ltd. (PEB)
  
  
• Panacea Pharmaceuticals, Inc.
  
  
• Pathwork Diagnostics (formerly Predicant Biosciences)
  
  
• Perceptronix Medical Inc.
  
  
• PerkinElmer, Inc.
  
  
• Perlegen Sciences, Inc.
  
  
• PersonaDX
  
  
• Power3 Medical Products, Inc.
  
  
• Precision Therapeutics
  
  
• Predictive Biosciences
  
  
• PreMD Inc.
  
  
• Primagen Holding B.V.
  
  
• Proteome Systems Limited
  
  
• Provista Diagnostics (formerly Biomarker Technologies LLC)
  
  
• Qiagen N.V.
  
  
• Quest Diagnostics Incorporated
  
  
• RainDance Technologies, Inc. (RDT)
  
  
• Rational Therapeutics
  
  
• Response Genetics, Inc.
  
  
• Rosetta Genomics Ltd.
  
  
• Rubicon Genomics, Inc.
  
  
• Rules-Based Medicine, Inc.
  
  
• Saladax Biomedical, Inc. (SBI)
  
  
• Signet Laboratories, Inc.
  
  
• Source MDx
  
  
• Targeted Diagnostics & Therapeutics, Inc. (TDT)
  
  
• Targeted Molecular Diagnostics, LLC (TDM)
  
  
• Tripath Imaging, Inc.
  
  
• US LABS
  
  
• Ventana Medical Systems. Inc.
  
  
• Veridex, LLC
  
  
• Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.)
  
  
• Vision BioSystems Ltd/Danaher Corp.
  
  
• Vitatex Inc.
  
  
• Wako Chemicals USA
  
  
• WaveSense LLC
  
  
• Xenomics, Inc.
  
  
• Xytos Inc.
  
  
• Zila Inc.

License Note: Kalorama Information's listed default price on its information products reflects a single user license only. Purchasing a departmental license (up to 10 users at one location) or a global site license (entire company) permits multiple individuals in the company to benefit from this resource.  
 

CHAPTER ONE: EXECUTIVE SUMMARY

• Introduction
  
  
• Scope and Methodology
  
  
• Size and Growth of the Market
  
  
• Market Trends

CHAPTER TWO: INTRODUCTION

• Background
  
  
• Cancer: Diagnosis and Management of a Chronic Disease
  
  
• Point of View

CHAPTER THREE: TRENDS AND ISSUES IN COMMERCIALIZATION

• Background
  
  
• Demographics of Cancer, Worldwide
  
  
• Cancer Testing in the World—Screening and Government Supported Programs
  
  
  
  
  
  • An Aging World Population
    
    
  • United States of America
    
    
  • Europe
    
    
  • People’s Republic of China
    
    
  • India
    
    
  • Canada
  
  
  
• Reimbursement and Commercialization of Novel Tests
  
  
• Consumerism and Web-Based Test Services
  
  
• Regulatory Requirements of New Products
  
  
• Strategic Alliances—Rx-Dx and Dx-Dx Partnerships
  
  
• From Research to the Clinical Lab

CHAPTER FOUR: TECHNOLOGICAL TRENDS ENABLING THE FUTURE OF CANCER DIAGNOSTICS

• Background
  
  
• Biomarker Revolution
  
  
• The Promise of Personalized Medicine
  
  
• Miniaturization and Multiplexed Biological Assays
  
  
• The Search for Non-Invasive Tools
  
  
  
  
  
  • Serum
    
    
  • Saliva
    
    
  • Transdermal/Optical
    
    
  • Breath
    
    
  • Hair
    
    
  • Sputum
  
  
  
• Role of Immunoassays in Cancer Management
  
  
• New Technologies Applied To Cancer Diagnostics
  
  
  
  
  
  • Proteomics, Mass Spectroscopy and the Role of the Immune System
    
    
  • Methylated Gene (meDNA) Patterns
    
    
  • Circulating Cell-Free Nucleic Acids
    
    
  • RNA—Ribonucleic Acid
    
    
  • Stem Cell Markers
  
  
  
• The Role of In Vivo Diagnostics—In vivo Cellular and Molecular Imaging

CHAPTER FIVE: MARKET ANALYSIS—IN VITRO TESTS FOR CANCER

• Background
  
  
• World Segments of the Market for Cancer Diagnostics
  
  
• Companies and Products
  
  
  
  
  
  • Screening Tests
    
    
    
    
    
    • DR-70
      
      
    • HAAH
      
      
    • ECPKA
      
      
    • The Cancer Profile
    
    
    
  • Cancer-Specific Tests
    
    
    
    
    
    • Bladder Cancer
      
      
    • Breast Cancer
      
      
    • Cervical Cancer
      
      
    • Colon Cancer
      
      
    • Lung Cancer
      
      
    • Ovarian Cancer
      
      
    • Prostate Cancer

CHAPTER SIX: MARKET ANALYSIS—CANCER TESTS IN IVD SEGMENTS

• Cancer Diagnostics and IVD Markets
  
  
• The Market For Cancer Tests In Clinical Chemistry
  
  
• The Market For Cancer Tests in Immunoassays—Lab-Based & Rapid
  
  
• The Market for Cancer Tests in Histology and Cytology
  
  
  
  
  
  • The Future of the Pap Smear & HPV Testing
    
    
  • IHC/ISH and Digital Cytometry
    
    
  • The Market for Tissue Microarrays
    
    
  • The Market for Cancer Tests in Flow Cytometry
    
    
  • The Market for Cancer Tests and Image Cytometry
  
  
  
• The Market for Circulating Tumor Cells in Cancer Diagnostics
  
  
• The Market for Molecular Assays in Cancer
  
  
• The Market for Pharmacodiagnostics Tests in Cancer
  
  
• The Market for Biochips and Arrays in Cancer Diagnostics
  
  
• Cancer Sample Preparation Techniques
  
  
• The Commercial Outlook for Cancer Diagnostics

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

• Conclusions
  
  
  
  
  
  • Conclusion One
    
    
    
    
    
    • Implication
    
    
    
  • Conclusion Two
    
    
    
    
    
    • Implication
    
    
    
  • Conclusion Three
    
    
    
    
    
    • Implication
    
    
    
  • Conclusion Four
    
    
    
    
    
    • Implication
    
    
    
  • Conclusion Five
    
    
    
    
    
    • Implication
    
    
    
  • Conclusion Six
    
    
    
    
    
    • Implication
  
  
  
• Unmet Market Needs
  
  
  
  
  
  • Unmet Need One
    
    
  • Unmet Need Two
    
    
  • Unmet Need Three

CHAPTER EIGHT: THE TOP TIER IVD COMPANIES AND THEIR INVESTMENT IN CANCER

• Abbott Diagnostics
  
  
  
  
  
  • Recent Revenue History
    
    
  • Key Comment
    
    
  • Details
    
    
    
    
    
    • Molecular Histology
      
      
    • PCR
      
      
    • Immunoassays
  
  
  
• Beckman Coulter, Inc.
  
  
  
  
  
  • Recent Revenue History
    
    
  • Key Comment
    
    
  • Details
    
    
    
    
    
    • Flow Cytometry
      
      
    • Cancer Immunoassays
      
      
    • FOB
  
  
  
• Becton Dickinson & Company
  
  
  
  
  
  • Recent Revenue History
    
    
  • Key Comment
    
    
  • Details
  
  
  
• bioMerieux Inc.
  
  
  
  
  
  • Recent Revenue History
    
    
  • Key Comment
    
    
  • Details
  
  
  
• Bio-Rad Laboratories Inc.
  
  
  
  
  
  • Key Comment
    
    
  • Details
  
  
  
• Inverness Medical Innovations, Inc.
  
  
  
  
  
  • Key Comment
    
    
  • Details
  
  
  
• Ortho Clinical Diagnostics
  
  
  
  
  
  • Key Comment
    
    
  • Details
  
  
  
• Roche Diagnostics
  
  
  
  
  
  • Key Comment
    
    
  • Details
  
  
  
• Siemens Medical Solutions Diagnostics
  
  
  
  
  
  • Recent Revenue History
    
    
  • Key Comment
    
    
  • Details
    
    
    
    
    
    • In vivo
      
      
    • Immunoassays
  
  
  
• Sysmex Corporation
  
  
  
  
  
  • Recent Revenue History
    
    
  • Key Comment
    
    
  • Details

CHAPTER NINE: NEW ENTRANTS AND NOVEL PRODUCT DEVELOPERS

• 20/20GeneSystems Inc.
  
  
• 454 Life Sciences Corporation
  
  
• A&G Pharmaceutical
  
  
• AdnaGen AG
  
  
• Affymetrix Inc.
  
  
• Agendia B.V.
  
  
• Agilent Technologies Inc.
  
  
• Alethia Biotherapeutics Inc.
  
  
• Almac Diagnostics (formerly ArraDx)
  
  
• Althea Technologies, Inc.
  
  
• Ambrilia Biopharma Inc.
  
  
• AMDL, Inc.
  
  
• American Diagnostica Inc.
  
  
• Aperio Technologies, Inc.
  
  
• Applied Genomics, Inc. (AGI)
  
  
• Applied Imaging Corp./Genetix
  
  
• Asuragen, Inc.
  
  
• AsymmetRx, Inc.
  
  
• AviaraDx (formerly Arcturus Biosciences)
  
  
• AVIVA Biosciences Corporation
  
  
• BioCurex, Inc.
  
  
• BioGenex Laboratories, Inc.
  
  
• BioImagene, Inc.
  
  
• Biomoda, Inc.
  
  
• BioMosaics
  
  
• BioNanomatrix
  
  
• Biophysical Corp.
  
  
• BioServe
  
  
• Biosite Incorporated
  
  
• BIOVIEW, Inc.
  
  
• Bostwick Laboratories, Inc.
  
  
• Bruker BioSciences Corporation
  
  
• CCC Diagnostics LLC
  
  
• Cancer Genetics, Inc.
  
  
• Cangen Biotechnologies, Inc.
  
  
• Celera
  
  
• Celerus Diagnostics
  
  
• Cellumen, Inc.
  
  
• CeMines, Inc.
  
  
• ChemSensing
  
  
• Clarient Inc. (formerly ChromaVision)
  
  
• CombiMatrix Molecular Diagnostics (CMDX)
  
  
• CompuCyte Corporation
  
  
• Correlogic Systems, Inc.
  
  
• CytoCore, Inc. (formerly Molecular Diagnostics, Inc.)
  
  
• Cytyc Corporation
  
  
• Dako A/S
  
  
• diaDexus Inc.
  
  
• DiaGenic ASA
  
  
• DiagnoCure
  
  
• Diamics, Inc.
  
  
• Digene Corporation (Acquired by Qiagen)
  
  
• DNA Direct, Inc.
  
  
• DxS
  
  
• eGene Inc.
  
  
• Epigenomics AG
  
  
• EXACT Sciences Corporation
  
  
• eXagen Diagnostics, Inc.
  
  
• Exiqon A/S
  
  
• Falcon Genomics, Inc.
  
  
• Fermiscan Holdings Limited (FER)
  
  
• Fluidigm Corporation
  
  
• Fujirebio Diagnostics. Inc. (FDI)
  
  
• GeneNews Limited (formerly ChondroGene Limited)
  
  
• GenoMed, Inc.
  
  
• Genomic Health
  
  
• Genoptix Inc.
  
  
• Gen-Probe Incorporated
  
  
• Genzyme Corporation
  
  
• Greiner Bio-One International AG
  
  
• Gynecor
  
  
• Health Discovery Corporation
  
  
• HistoRx, Inc,
  
  
• Ikonisys Inc.
  
  
• Illumina
  
  
• ImmunArray Ltd.
  
  
• Immunicon Corporation
  
  
• Immunotope, Inc.
  
  
• InterGenetics, Inc.
  
  
• Invirion Diagnostics, LLC
  
  
• Ipsogen
  
  
• Kronus Inc.
  
  
• Laboratory Corporation of America Holdings (LabCorp)
  
  
• Luminex Corporation
  
  
• MacroArray Technologies, LLC
  
  
• Matritech
  
  
• MDS/Molecular Devices Corporation
  
  
• Med BioGene, Inc. (MBI)
  
  
• Menssana Research, Inc.
  
  
• Micronics Inc.
  
  
• Miraculins Inc.
  
  
• Modern Technology Corp.
  
  
• MolecularMD
  
  
• MonoGen
  
  
• Monogram Biosciences Inc. (formerly Virologic, Inc.)
  
  
• mtm laboratories AG
  
  
• Myriad Genetics, Inc.
  
  
• NeoMatrix, LLC
  
  
• NorChip
  
  
• NorDiag ASA
  
  
• Nuvera Biosciences
  
  
• Olympus Life and Material Science Europa, GMBH
  
  
• Onco Detectors International LLC
  
  
• Oncolab Inc.
  
  
• OncoMethylome Sciences S.A.
  
  
• Onconome, Inc. (formerly Tessera Diagnostics)
  
  
• One Cell Systems, Inc.
  
  
• Orion Genomics
  
  
• Oxford Genome Sciences Ltd. (OGeS)
  
  
• OXIS International
  
  
• Pacific Edge Biotechnology Ltd. (PEB)
  
  
• Panacea Pharmaceuticals, Inc.
  
  
• Pathwork Diagnostics (formerly Predicant Biosciences)
  
  
• Perceptronix Medical Inc.
  
  
• PerkinElmer, Inc.
  
  
• Perlegen Sciences, Inc.
  
  
• PersonaDX
  
  
• Power3 Medical Products, Inc.
  
  
• Precision Therapeutics
  
  
• Predictive Biosciences
  
  
• PreMD Inc.
  
  
• Primagen Holding B.V.
  
  
• Proteome Systems Limited
  
  
• Provista Diagnostics (formerly Biomarker Technologies LLC)
  
  
• Qiagen N.V.
  
  
• Quest Diagnostics Incorporated
  
  
• RainDance Technologies, Inc. (RDT)
  
  
• Rational Therapeutics
  
  
• Response Genetics, Inc.
  
  
• Rosetta Genomics Ltd.
  
  
• Rubicon Genomics, Inc.
  
  
• Rules-Based Medicine, Inc.
  
  
• Saladax Biomedical, Inc. (SBI)
  
  
• Signet Laboratories, Inc.
  
  
• Source MDx
  
  
• Targeted Diagnostics & Therapeutics, Inc. (TDT)
  
  
• Targeted Molecular Diagnostics, LLC (TDM)
  
  
• Tripath Imaging, Inc.
  
  
• US LABS
  
  
• Ventana Medical Systems. Inc.
  
  
• Veridex, LLC
  
  
• Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.)
  
  
• Vision BioSystems Ltd/Danaher Corp.
  
  
• Vitatex Inc.
  
  
• Wako Chemicals USA
  
  
• WaveSense LLC
  
  
• Xenomics, Inc.
  
  
• Xytos Inc.
  
  
• Zila Inc.

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: Market Summary Worldwide Market for In Vitro Cancer Diagnostics 2004-2009

CHAPTER THREE: TRENDS AND ISSUES IN COMMERCIALIZATION

• Table 3-1: Major Cancer Incidence Estimates by Cancer Type and Geographic Market Development (More Developed vs Less Developed) 2000
  
  
  
  
  
• Table 3-2: Worldwide Major Cancer Incidence and Mortality Estimates by Cancer Type, 2000
  
  
• Table 3-3: Old-Age Dependency Ratios Comparative Projections by Leading Country 2000, 2025
  
  
  
  
  
• Table 3-4: Selected DTC Cancer Tests
  
  
  
  
  
• Table 3-5: Selected Company Alignments for Cancer Diagnostics, 2005 - 2007
  
  
  
  
  
• Table 3-6: Selected Agreements Between Companies and Reference Laboratories
  
  
  
  
  
• Table 3-7: Selected Tests Offered by Company Accredited Laboratories
  
  
  
  
  
• Table 3-8: Selected IVDs used in Drug Development

CHAPTER FOUR: TECHNOLOGICAL TRENDS ENABLING THE FUTURE OF CANCER DIAGNOSTICS

• Table 4-1: Selected Tumor Markers as Applied to Specific Cancers and Drugs
  
  
  
  
  
• Table 4-2: Selected Chemotherapy Resistance Tests
  
  
  
  
  
• Table 4-3: Selected Arrays and Biochip Tests for Cancer
  
  
• Table 4-4: Selected Non-Invasive Cancer Tests (Company, Sample, Test Details, Marketing Status)
  
  
  
  
  
• Table 4-5: Selected Methylated DNA Tests (Company, Technology, Test Details, Marketing Status)
  
  
  
  
  
• Table 4-6: Selected RNA-Based Cancer Tests

CHAPTER FIVE: MARKET ANALYSIS—IN VITRO TESTS FOR CANCER

• Table 5-1: Cancer Demographics: Populations, Cancer Incidence, Share of Incidence, and Share of IVD Cancer Market by Geographic Region 2005
  
  
  
  
  
• Table 5-2: World Cancer Test Sales by Geographic Region (North America, Europe, Japan, Rest of World) 2007-2012
  
  
  
  
  
• Table 5-3: Cancer Diagnostics and the Top Tier IVD Companies Segments of Participation 2005
  
  
  
  
  
• Table 5-4: Revenues of Selected Cancer Diagnostic Companies 2001-2005
  
  
  
  
  
• Table 5-5: Selected Breast Cancer Test Innovations
  
  
  
  
  
• Table 5-6: Selected FOB Test Innovations
  
  
  
  
  
• Table 5-7: Selected Prostate Cancer Test Innovations (Company, Test Details, Marketing Status)

CHAPTER SIX: MARKET ANALYSIS—CANCER TESTS IN IVD SEGMENTS

• Table 6-1: Worldwide Market for Selected Cancer In Vitro Diagnostics Revenues and Growth Rate by Testing Segment (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating Tumor Cells, Pharmacodiagnostics) 2007-2012
  
  
  
  
  
• Table 6-2: Selected Tissue Function Clinical Chemistry Tests
  
  

  
  
  

  
  
  
• Table 6-3: Major Players For Clinical Chemistry Analyzers And Reagents
  
  
  
  
  
• Table 6-4: Lab-Based Cancer Immunoassay Sales 2004-2009
  
  
  
  
  
• Table 6-5: Potential Cancer Biomarkers
  
  
  
  
  
• Table 6-6: Selected Cancer Immunoassay Innovations
  
  
  
  
  
• Table 6-7: Worldwide Rapid Cancer Test Sales by Test Category (Fecal Occult Blood, PSA, H. pylori, NMP22, Other) 2004-2009
  
  
  
  
  
• Table 6-8: Worldwide Histology/Cytology Sales by Test Type (Traditional non-Pap, Pap, IHC, ISH) 2004-2009
  
  
  
  
  
• Table 6-9: Top Vendors of Traditional Histology Stains
  
  
• Figure 6-1: Geographical Distribution of Pap Testing Volume (in millions of tests) by Region (U.S., Europe, Japan, ROW)
  
  
  
  
  
• Table 6-10: Selected Automated Pap Systems
  
  
  
  
  
• Table 6-11: Selected HPV test innovators
  
  
  
  
  
• Table 6-12: Selected IHC and ISH Product Companies
  
  
  
  
  
• Table 6-13: Major Protein and Molecular Markers Used in Tissue Staining
  
  
  
  
  
• Table 6-14: Selected Digital Pathology Systems
  
  
• Figure 6-2: The Market for Tissue Microarrays in Clinical Labs 2007-2012
  
  
  
  
  
• Table 6-15: Selected Laser Microdissection Instruments
  
  
  
  
  
• Table 6-16: Selected Flow Cytometry Innovation (Company, Technology Details, Marketing Status)
  
  
  
  
  
• Figure 6-3: The World Market for Clinical Flow Cytometry 2007-2012
  
  
  
  
  
• Figure 6-4: The World Market for Clinical Image Cytometry Systems, Reagents, and Consumables 2007-2012
  
  
  
  
  
• Table 6-17: Selected Circulating Tumor Cell Products (Company, Technology, Product Details, Marketing Status)
  
  
  
  
  
• Figure 6-5: The World Market for Commercial CTC-Based Diagnostic Tests 2007-2012
  
  
  
  
  
• Table 6-18: Selected Molecular Tests for Cancer
  
  
  
  
  
• Figure 6-6: The World Market for Commercial Pharmacodiagnostics Cancer Tests 2007-2012
  
  
  
  
  
• Table 6-19: Selected Cancer Pharmacodiagnostic Tests (Company, Test Details, Marketing Status)
  
  
  
  
  
• Figure 6-7: World Market for DNA Test Sample Preparation Reagents
  
  
  
  
  
• Figure 6-8: Technology Penetration Forecast for Cancer IVDs 2007-2025